NEW YORK – Proteomics firm Nomic Bio (formerly nplex bioscience) said Wednesday it has closed a $17 million Series A funding round.
The company said it will use the funds to grow its teams at its Montreal and Boston headquarters and expand the throughput and multiplexing capabilities of its nELISA platform.
The round was led by Lux Capital and joined by SR One and Casdin Capital, with participation from prior institutional investors. Nomic has now raised more than $21 million in funding total.
Based on technology developed in the lab of David Juncker, professor of biomedical engineering at McGill University, the nELISA platform uses a miniaturized, bead-based-ELISA format to multiplex hundreds to thousands of immunoassays rapidly and without the problem of antibody cross-reactivity. According to the company, it aims by Q2 2022 to be able to process 100,000 samples per quarter with up to 500 proteins measured per sample.
"It's evident that the next leap in understanding and treating disease will come from building atop the emerging omic-stack," Zavain Dar, partner at Lux Capital, said in a statement. "What’s been sorely lacking is the ability to analyze the proteome as easily as the genome, and the Lux team is confident that Nomic has taken the right approach in tackling that challenge. Their technology enables optimal scalability in both content and throughput without compromising on cost, accuracy, or translatability."
"Our mission is to improve human health by providing scientists with the tools they need to measure proteins at high resolution and unprecedented scale and cost in order to make better decisions on targets, drugs, and biomarkers," said Milad Dagher, Nomic's cofounder and CEO.